Next-generation sequencing of circulating tumor DNA for metastatic non-small cell lung cancer: a discussion on its implementation in the Brazilian clinical practice

Future Oncol. 2021 Jan;17(2):205-213. doi: 10.2217/fon-2020-0583. Epub 2020 Oct 14.

Abstract

The objective of this review is to address the barriers limiting access to next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) for metastatic nonsquamous non-small cell lung cancer in Brazil and to propose its implementation in practice. A selected panel of lung cancer experts was provided with relevant prompts to address at a conference; a paper was then compiled on the topic. The authors propose specific and realistic recommendations for implementing access to ctDNA NGS. Further, the authors address all barriers and impediments mentioned within this review. There is a great need to increase ctDNA NGS for cancer care in Brazil. Adapting the current cancer testing framework is essential to expanding the use of this tool.

Keywords: Brazil; NGS; NSCLC; circulating tumor DNA; metastatic; next-generation sequencing; non-small cell lung cancer.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor*
  • Brazil
  • Carcinoma, Non-Small-Cell Lung / blood
  • Carcinoma, Non-Small-Cell Lung / diagnosis*
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / therapy
  • Circulating Tumor DNA*
  • Clinical Decision-Making
  • DNA Mutational Analysis
  • Disease Management
  • High-Throughput Nucleotide Sequencing* / methods
  • Humans
  • Lung Neoplasms / blood
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / therapy
  • Molecular Targeted Therapy / adverse effects
  • Molecular Targeted Therapy / methods
  • Mutation
  • Neoplasm Staging
  • Practice Patterns, Physicians'
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • Circulating Tumor DNA